JP2019524701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524701A5 JP2019524701A5 JP2019500245A JP2019500245A JP2019524701A5 JP 2019524701 A5 JP2019524701 A5 JP 2019524701A5 JP 2019500245 A JP2019500245 A JP 2019500245A JP 2019500245 A JP2019500245 A JP 2019500245A JP 2019524701 A5 JP2019524701 A5 JP 2019524701A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antagonist
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940124060 PD-1 antagonist Drugs 0.000 claims 10
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims 10
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359073P | 2016-07-06 | 2016-07-06 | |
| US62/359,073 | 2016-07-06 | ||
| PCT/US2017/040665 WO2018009507A1 (en) | 2016-07-06 | 2017-07-05 | Combination of tim-4 antagonist and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524701A JP2019524701A (ja) | 2019-09-05 |
| JP2019524701A5 true JP2019524701A5 (enExample) | 2020-08-13 |
| JP7164512B2 JP7164512B2 (ja) | 2022-11-01 |
Family
ID=59366515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500245A Active JP7164512B2 (ja) | 2016-07-06 | 2017-07-05 | Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11306143B2 (enExample) |
| EP (1) | EP3481866B1 (enExample) |
| JP (1) | JP7164512B2 (enExample) |
| KR (1) | KR102602137B1 (enExample) |
| CN (1) | CN109641968B (enExample) |
| ES (1) | ES2992868T3 (enExample) |
| WO (1) | WO2018009507A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20151102T1 (xx) * | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| US11306143B2 (en) | 2016-07-06 | 2022-04-19 | Bristol-Myers Squibb Company | Combination of TIM-4 antagonist and PD-1 antagonist and methods of use |
| WO2021064184A1 (en) * | 2019-10-04 | 2021-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
| CN110982824B (zh) * | 2019-10-09 | 2022-04-15 | 天津大学 | 拮抗pd-1的抗体类似物bp基因及蛋白和应用 |
| US11774451B2 (en) * | 2019-11-21 | 2023-10-03 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular vibrational spectroscopic markers for detection of cancer |
| US20250177340A1 (en) * | 2021-01-29 | 2025-06-05 | Lapix Therapeutics, Inc. | Tartaric Acid Analogs and Uses Thereof |
| CA3228331A1 (en) * | 2021-08-10 | 2023-02-16 | Karla FRIETZE | Generation and characterization of novel tim-4 binding agents |
| KR20240046882A (ko) | 2021-08-13 | 2024-04-11 | 라픽스 테라퓨틱스, 인코포레이티드 | 면역 불내성의 감소 및 자가면역 장애의 치료를 위한 조성물 및 방법 |
| CN115957304A (zh) * | 2022-10-18 | 2023-04-14 | 山东大学 | Tim-4调控胆固醇合成中的应用 |
| EP4649098A1 (en) * | 2023-01-13 | 2025-11-19 | Shanghai Kaijin Biotechnology , Ltd | Multi-specific polypeptide complexes |
| WO2025077833A1 (en) * | 2023-10-11 | 2025-04-17 | Suzhou Neologics Bioscience Co., Ltd. | Antibodies targeting tim-3 and pd-1 and uses thereof |
| CN117904122B (zh) * | 2023-12-22 | 2025-01-28 | 北京贝来药业有限公司 | 一种编码抗pd-1抗体的基因及其修饰干细胞的制备和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| KR100246529B1 (ko) | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | 수용체 관련된 신호 변환 경로를 위한 키메라 사슬 |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
| TW200539890A (en) * | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| CN101035561A (zh) | 2004-03-24 | 2007-09-12 | 特罗斯药品公司 | 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法 |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JP2015209376A (ja) * | 2014-04-24 | 2015-11-24 | 国立大学法人北海道大学 | 腫瘍特異的免疫増強剤 |
| US11306143B2 (en) | 2016-07-06 | 2022-04-19 | Bristol-Myers Squibb Company | Combination of TIM-4 antagonist and PD-1 antagonist and methods of use |
-
2017
- 2017-07-05 US US16/314,732 patent/US11306143B2/en active Active
- 2017-07-05 CN CN201780054101.9A patent/CN109641968B/zh active Active
- 2017-07-05 EP EP17740851.5A patent/EP3481866B1/en active Active
- 2017-07-05 WO PCT/US2017/040665 patent/WO2018009507A1/en not_active Ceased
- 2017-07-05 ES ES17740851T patent/ES2992868T3/es active Active
- 2017-07-05 KR KR1020197003493A patent/KR102602137B1/ko active Active
- 2017-07-05 JP JP2019500245A patent/JP7164512B2/ja active Active
-
2022
- 2022-03-14 US US17/693,975 patent/US12227575B2/en active Active